Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
[HTML][HTML] Current therapy and drug resistance in metastatic castration-resistant prostate cancer
M Cai, XL Song, XA Li, M Chen, J Guo, DH Yang… - Drug Resistance …, 2023 - Elsevier
Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase …
Background Metastatic castration-resistant prostate cancer is enriched in DNA damage
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …
PARP and PARG inhibitors in cancer treatment
D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …
genomic instability through radiotherapy and chemotherapy has been a powerful but …
State-of-the-art strategies for targeting the DNA damage response in cancer
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …
damage response (DDR) and/or increased replication stress. These alterations promote the …
The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
Complete and accurate DNA replication requires the progression of replication forks through
DNA damage, actively transcribed regions, structured DNA and compact chromatin. Recent …
DNA damage, actively transcribed regions, structured DNA and compact chromatin. Recent …
[HTML][HTML] A decade of clinical development of PARP inhibitors in perspective
Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …
Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the …
Purpose: Genomic alterations in DNA damage repair (DDR) genes other than BRCA may
confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate …
confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate …
[HTML][HTML] The emerging role of cell-free DNA as a molecular marker for cancer management
AJ Bronkhorst, V Ungerer, S Holdenrieder - Biomolecular detection and …, 2019 - Elsevier
An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …
[HTML][HTML] ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
Background Homologous recombination repair deficiency (HRD) is a frequent feature of
high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is …
high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is …